The Spring 2018 newsletter features stories about a geriatrician who builds homes for older adults; why young people are especially at risk for HIV; U.S. military space systems vulnerable to attacks (cyber and otherwise); and genetic testing with its troubling implications when it comes to screening for disorders and disabilities in embryos.
The Winter 2018 newsletter spotlights stories about what happens when we let technology help care for aging parents; rheumatoid arthritis, which affects over 1.4 million people in the U.S.; abortion doulas who offer comfort to women at a complicated time; and a potential new weapon in the fight to eradicate HIV.
The Fall 2017 Real to Reel newsletter features stories about many older adults falling victim to guardianship scams, how abortion waits increase all kinds of risk, a rising star's death from AIDS-related complications, and a pregnancy risk that's the leading cause of maternal mortality in the first trimester.
The Summer 2017 Real to Reel newsletter spotlights stories about the staggering HIV infection rate in Southern states like Mississippi, how the "abortion pill" has opened a new front in the war over reproductive rights, the names and faces behind the high maternal mortality rate in the U.S. and much more.
Our special edition of Real to Reel focuses on maternal health, childbirth and abortion, with stories that include the death of a neonatal nurse after giving birth to her daughter, designing a better hospital to reduce C-sections, a home birth with some unexpected twists and much more.
The Spring 2017 Real to Reel spotlights stories about depression and pregnancy, a genetic link that might hold the key to ending the opioid epidemic, the U.S. nuclear command-and-control center at Cheyenne Mountain, and a Southern Christian doctor who believes the abortions he provides are rooted in justice.
The Winter 2017 Real to Reel spotlights stories about a 16-year-old's long-ago journey to obtain a legal abortion in Japan; the risk over flawed safeguards for the U.S. nuclear arsenal; why members of minority communities face obstacles in joining clinical trials; and the battle within the war against the opioid epidemic.